Xenoport Inc.'s guidance for even-higher sales of Horizant (gabapentin enacarbil) in postherpetic neuralgia and restless legs syndrome (RLS) sparked analyst speculation about potential specialty pharma interest in the compound and about the odds of phase II success for XP23829, due to report psoriasis data in the third quarter of this year.